Sanofi and Regeneron’s Kevzara (sarilumab) Fails in P-III Trial for Patients with COVID-19 in the US
Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy
Shots:
- The P-III study assessing Kevzara (400mg) + BSC vs BSC in 194 patients with COVID-19 requiring mechanical ventilation did not meet it’s 1EPs & 2EPs
- Based on the results, the companies have stopped the US-based study that includes the second cohort of patients receiving a higher dose of Kevzara (800 mg)
- The IDMC is managing both the Regeneron-led US trial and the Sanofi-led trial outside of the US and has recommended that the trial outside the US using a different dosing regimen should continue with its anticipated results in Q3’20
Click here to read full press release/ article | Ref: Sanofi | Image: WSJ